Application and Validation of Simple Isocratic HPLC-UV-DAD Method with Dual Wavelength Detection for Ivabradine Determination and Its Application in the Study of Stress Degradation
Open Access
- 7 August 2017
- journal article
- research article
- Published by Wiley in Journal of Chemistry
- Vol. 2017, 1-7
Abstract
Ivabradine is a modern drug that selectively lowers the heart rate, improves cardiac energy balance, and reduces heart’s demands for oxygen and energy. Due to the chemical nature of ivabradine, which absorbs light at 207 nm and 286 nm, its detection was performed at two wavelengths. A Knauer C8 column was used to develop the RP-HPLC method for determination of ivabradine. The proposed method was linear from 5 to 100 µg/ml () for both wavelengths and limits of detection (LOD) and limits of quantification (LOQ) were 0.33 and 1.09 µg/ml for 207 nm and 1.19 and 3.97 µg/ml for 286 nm, respectively. After validation, the investigated method was applied to a stress degradation study. Numerous degradation products were formed from ivabradine solutions through alkaline and acid hydrolysis, oxidation, and photolysis. The largest numbers of degradation products were found in the sample exposed to 24 h radiation and alkaline hydrolysis (eight and six products, resp.). Finally, the simple method using HPLC-UV-DAD was developed and validated. Its usefulness for the monitoring of possible degradation products was demonstrated.
Keywords
This publication has 15 references indexed in Scilit:
- EFFECT OF NON-AQUEOUS AND BUFFERED MOBILE-PHASE COMPOSITION ON THE RETENTION OF IVABRADINEJournal of Liquid Chromatography & Related Technologies, 2014
- Chromatographic analysis of ivabradine on polar, nonpolar and chemically modified adsorbents by HPTLCJournal of Food and Drug Analysis, 2013
- Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled studyThe Lancet, 2010
- The Role of the Funny Current in Pacemaker ActivityCirculation Research, 2010
- HCN channels: Structure, cellular regulation and physiological functionCellular and Molecular Life Sciences, 2008
- Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trialThe Lancet, 2008
- Ivabradine - the first selective sinus node If channel inhibitor in the treatment of stable anginaInternational Journal Of Clinical Practice, 2006
- Simultaneous determination of ivabradine and its metabolites in human plasma by liquid chromatography–tandem mass spectrometryJournal of Chromatography B: Biomedical Sciences and Applications, 2000
- Two pacemaker channels from human heart with profoundly different activation kineticsThe EMBO Journal, 1999
- Determination of ivabradine and its N-demethylated metabolite in human plasma and urine, and in rat and dog plasma by a validated high-performance liquid chromatographic method with fluorescence detectionJournal of Chromatography B: Biomedical Sciences and Applications, 1998